Controlled study of decision-making and cognitive impairment in Parkinson's disease

Movement Disorders

Volumn 22, Issue 10, 2007, Pages 1430-1435

  Pagonabarraga, Javier ^a   García Sánchez, Carmen ^a   Llebaria, Gisela ^a   Pascual Sedano, Berta ^a   Gironell, Alexandre ^a   Kulisevsky, Jaime ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Cognitive; Impulsive disorders; Iowa gambling task; Neuropsychiatry; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DYSFUNCTION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DECISION MAKING; DEMOGRAPHY; DRUG RESPONSE; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; IOWA GAMBLING TASK; MALE; MATTIS DEMENTIA RATING SCALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; REY AUDITORY VERBAL LEARNING TEST; STROOP AND DIGIT SPAN TEST; VERBAL BEHAVIOR;

AGED; CASE-CONTROL STUDIES; COGNITION DISORDERS; DECISION MAKING; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 34548007918     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21457     Document Type: Article

References (52)

1. Schrag A. Psychiatric aspects of Parkinson's disease. J Neurol 2004;251:795-804.
2. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Impact of psychiatric and other non-motor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004;52:784-788.
3. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67: 492-496.
4. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B. A multicentric cross-sectional survey of the prevalence and correlates of neuropsychiatric symptoms in a population of Parkinson's disease without dementia. Neurology 2006;66 (Suppl 2):A124-A125.
5. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-872.
6. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's Disease. Mov Disord 2005;20:77-81.
7. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
8. Martin-Soelch C, Leenders KL, Chevalley AF, et al. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Rev 2001;36:139-149.
9. Zahm DS. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 2000;24:85-105.
10. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003;41: 1431-1441.
11. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
12. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
13. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
14. Berke JD, Hyman SE. Addiction, dopamine, and the review molecular mechanisms of memory. Neuron 2000;25:515-532.
15. Bechara A, Tranel D, Damasio H. Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 2000;123:2189-2202.
16. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science 1997;275:1293-1295.
17. Northoff G, Grimm S, Boeker H, et al. Affective judgment and beneficial decision making: ventromedial prefrontal activity correlates with performance in the Iowa Gambling Task. Hum Brain Mapp 2006;27:572-587.
18. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm 2003;110:1289-1301.
19. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.
20. Perretta JG, Pari G, Beninger RJ. Effects of Parkinson's disease on two putative nondeclarative learning tasks. Cogn Behav Neurol 2005;18:185-192.
21. Mimura M, Oeda R, Kawamura M. Impaired decision-making in Parkinson's disease. Parkinsonism Relat Disord 2006;12:169-175.
22. Bechara A, Damasio H, Tranel D, Anderson SW. Dissociation of working memory from decision making within the human prefrontal cortex. J Neurosci 1998;18:428-437.
23. Fellows LK, Farah MJ. Different underlying impairments in decision-making following ventromedial and dorsolateral frontal lobe damage in humans. Cereb Cortex 2005;15:58-63.
24. Hugues AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;155:181-184.
25. Vingerhoets FJG, Villemure JG, Temperli P, Polio C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002;58:396-401.
26. Grosset K. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-1374.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
28. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed (DMS-IV). Washington, DC: American Psychiatric Association; 1994.
30. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.
31. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-P), version 2. New York: Biometrics Research, New York State Psychiatric Institute; 1995.
32. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease.Clin Neuropharmacol 2002;25:318-324.
33. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
34. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS. Neuropsychological assessment, 4th ed. New York: Oxford University Press; 2004.
35. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
36. Mimura M, Oeda R, Kawamura M. Impaired decision-making in Parkinson's disease. Parkinsonism Relat Disord 2006;12:169-175.
37. Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 1999;19:5473-5481.
38. Goudriaana AE, Oosterlaanb J, Beursc E, Brinkd W. Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Cogn Brain Res 2005;23:137-151.
39. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
40. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006;29:565-598.
41. Goerendt IK, Lawrence AD, Brooks DJ. Reward processing in health and Parkinson's disease: neural organization and reorganization. Cereb Cortex 2004;14:73-80.
42. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for β-CFT binding with positron emission tomography. Ann Neurol 1999;45:601-610.
43. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005;20 (Suppl 11):S17-S22.
44. D'Esposito M, Postle BR, Ballard D, Lease J. Maintenance versus manipulation of information held in working memory: an event-related fMRI study. Brain Cogn 1999;41:66-86.
45. Leung HC, Skudlarski P, Gatenby JC, Peterson BS, Gore JC. An event-related functional MRI of the Stroop Color Word Interference Task. Cereb Cortex 2000;10:552-560.
46. Costafreda SG, Fu CH, Lee L, Everitt B, Brammer MJ, David AS. A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum Brain Mapp 2006;27:799-810.
47. Petrides M. Lateral prefrontal cortex: architectonic and functional organization. Philos Trans R Soc Lond B Biol Sci 2005;360:781-795.
48. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001; 11:1136-1143.
49. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125:584-594.
50. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000;16:365-379.
51. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-626.
52. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.